Evidence map›Paper›PMID 41365534›Full record

ReviewJournal for immunotherapy of cancer2025

Functional genomics for improving adoptive T-cell transfer therapies.

Joseph G Skeate, Chang-Jung Lee, Carli Stewart, Mathew J Fischbach, Bibekananda Kar, Alexander K Tsai, Saad S Kenderian, Ingunn M Stromnes, David A Largaespada, Branden S Moriarity and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Journal for immunotherapy of cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joseph G SkeateDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0002-1765-5949
Chang-Jung LeeMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0009-0008-9841-1874
Carli StewartDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.ORCID http://orcid.org/0000-0002-2288-2230
Mathew J FischbachDepartment of Computer Science and Engineering, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0002-2849-4423
Bibekananda KarDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
Alexander K TsaiDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0002-4014-1946
Saad S KenderianT Cell Engineering Laboratory Program, Mayo Clinic, Rochester, Minnesota, USA.
Ingunn M StromnesMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0001-8120-4547
David A LargaespadaDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0002-3183-0491
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
Laura M RogersDepartment of Immunology, Mayo Clinic, Rochester, Minnesota, USA Rogers.Laura@mayo.edu.ORCID http://orcid.org/0000-0003-0861-3269

Funding

TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Aak1 to increase infiltration of adoptively transferred cells into solid tumorsR37CA276005 · NCI · MAYO CLINIC ROCHESTER · PI Laura Marie Rogers · 2023 to 2026
$1.8M
NCI NIH HHS R37 CA276005NCI NIH HHS T32 CA009138
6 · The paper itself

Abstract

Adoptive cell therapy (ACT) has shown remarkable success in the treatment of some malignancies, particularly leukemia. However, there are multiple factors that limit the durability of ACT in solid tumors, including dose-limiting toxicities, the immunosuppressive tumor microenvironment, and T-cell exhaustion. As the manufacture and preparation of adoptive T-cell therapies allows time and adequate conditions for ex vivo T-cell engineering, forward genetic screens can identify novel genetic targets that could improve their effectiveness. CRISPR is a commonly used functional genomics tool that has been successfully used to both enhance our understanding of mechanisms of resistance and to discover potential genetic edits to improve ACT. A complementary approach, Sleeping Beauty transposon mutagenesis provides additional opportunities to identify novel genetic edits without being constrained by the annotated human genome. Here, we summarize forward genetic screens and their tools to uncover strategies to enhance ACT. Complementary approaches can be combined and improved on to identify translatable genetic editing strategies through studies that accurately recapitulate disease-specific challenges.

Indexed as

GenomicsImmunotherapy, AdoptiveNeoplasmsT-LymphocytesAnimalsCRISPR-Cas SystemsGene EditingHumansAdoptive cell therapy - ACTGenomeNext generation sequencing - NGSTumor microenvironment - TME

Identifiers

PMID41365534
PMCPMC12699624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.